Rybelsus
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Rybelsus?
Semaglutide as a daily tablet at 3, 7 and 14 mg, approved for adults with type 2 diabetes, both for glucose control and to cut the chance of a heart attack, stroke or cardiovascular death when that risk is high.
In the US it is being discontinued: on June 4, 2026 the FDA listed all three strengths as discontinued, to be replaced by Ozempic tablets (1.5, 4 and 9 mg), the same medicine reformulated, and the doses do not convert milligram for milligram. It is also the drug behind the 33% levothyroxine AUC interaction warning. The oral route is the whole complication: it only absorbs under strict fasting conditions, which is why sellers offering “oral semaglutide” owe you a straight answer about what is in it.
Related reading: Is Rybelsus Being Discontinued? What Happened and the Ozempic Pill Switch
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Rybelsus comes up on this site
On GLP Watchdog, Rybelsus comes up in 8 research articles, 5 seller reviews, 3 FDA warning letters and 3 tools. Browse the FDA warning letters.
Research that discusses it
- Rybelsus for Weight Loss: How Much Weight People Lose, and Why It's Less
- Mounjaro Alternatives: What Costs Less and What You Give Up
- Which Drugs Are GLP-1s? Mounjaro, Trulicity, Phentermine and 25 More, Checked
- Coffee on Ozempic, Wegovy or Mounjaro: What the Labels and Studies Say
- Levothyroxine and a GLP-1: Why Your Thyroid Dose May Need to Come Down
- Does Blue Cross Cover Zepbound and Wegovy? Four Blue Plans, Four Different Answers
- All 8 articles are on the research page
Drug pages
Tools that use it
Seller reviews that mention it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers